Catalog No.: PC-73445Not For Human Use, Lab Use Only.
Sovleplenib (HMPL-523) is a highly potent, selective, orally available SYK inhibitor with IC50 of 25 nM, demonstrates anti-tumor activity in B cell lymphomas.
Sovleplenib (HMPL-523) is a highly potent, selective, orally available SYK inhibitor with IC50 of 25 nM, demonstrates anti-tumor activity in B cell lymphomas.
HMPL-523 blocked phosphorylation of BLNK, downstream protein of Syk, in human mantle cell line REC-1 and human plasma cell line ARH-7777 with IC50 of 0.105 µM and 0.173 μM, respectively.
HMPL-523 also inhibited cell viability of Ba/F3 Tel-Syk with IC50 of 0.033 μM.
HMPL-523 potently inhibited cell viability in a panel of B -cell lymphoma cell lines with SYK/BCR deregulation with IC50 of 0.4 to 2 μM.
HMPL-523 increased the apoptotic rate of REC-1 cells, showed the synergistic activities on killing human DLBCL in combination with BTK inhibitor, PI3Kδ inhibitors and Bcl2 family inhibitor.
HMPL-523 (100 mg/kg, p.o.) showed potent anti-tumor activity in B cell lymphoma REC-1, demonstrated anti-tumor activity in Syk dependent xenograft models.
